Foscarbidopa
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 45 publications
The current status of pump therapy options for advanced Parkinson's disease in Hungary
Journal: Ideggyogyaszati szemle
Published: June 03, 2026
Do We Need to Monitor B-Vitamins and Homocysteine During Initiation of Foslevodopa/Foscarbidopa Therapy?
Journal: Movement disorders : official journal of the Movement Disorder Society
Published: May 05, 2026
Beyond "Advanced": proposing Fluctuation-Dominant Parkinson's disease as a functional alternative to enable timely device-aided therapy.
Journal: Journal of neural transmission (Vienna, Austria : 1996)
Published: April 04, 2026
Opicapone as Add-On Therapy to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion: Clinical Improvement and Wearable Sensor-Based Gait Analysis.
Journal: Brain sciences
Published: March 21, 2026
Effect of subcutaneous foslevodopa/foscarbidopa therapy on non-motor symptoms in advanced PD patients.
Journal: Journal of neurology
Published: March 11, 2026
Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson's Disease: ROSSINI Study 6-Month Interim Results.
Journal: Neurology and therapy
Published: February 27, 2026
The underrated value of non-motor symptoms of Parkinson's disease in making diagnostic and treatment decisions.
Journal: Neurologia i neurochirurgia polska
Published: January 21, 2026
Peripheral Neuropathy during Subcutaneous Foslevodopa/Foscarbidopa Infusion in Parkinson's Disease: A Case Series.
Journal: Movement disorders clinical practice
Published: January 20, 2026
Foslevodopa/Foscarbidopa Subcutaneous Infusion Safety and Efficacy in Patients with and Without Prior Deep Brain Stimulation.
Journal: Advances in therapy
Published: December 26, 2025
Pharmacokinetics and pharmacodynamics of anti-Parkinson drugs in geriatric patients : Key for optimization of treatment
Journal: Zeitschrift fur Gerontologie und Geriatrie
Published: December 19, 2025
Diurnal-Only Foslevodopa/Foscarbidopa.
Journal: Movement disorders clinical practice
Published: December 03, 2025
Neuropsychiatric and Cognitive Safety of Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: Insights From a Real-World Cohort.
Journal: Journal of movement disorders
Published: November 12, 2025
Last Updated: 06/30/2026